ArticleFrontiers in immunology2026
Clinical phenotype and prognostic determinants of spontaneous pneumomediastinum in anti-MDA5 antibody-positive dermatomyositis.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: To identify the clinical phenotype and prognostic determinants in patients with anti-MDA5 antibody-positive dermatomyositis (MDA5+DM) with spontaneous pneumomediastinum (SPM). Methods: We retrospectively analyzed 150 MDA5+DM patients (50 with SPM and 100 without). Clinical, laboratory, and therapeutic profiles were analyzed. Multivariable logistic regression was used to identify factors associated with survival in the SPM cohort. Results: The SPM group had a significantly higher 6-month mortality than the non-SPM group (54% vs. 16%, P<0.001). Patients with SPM were older and less frequently had arthralgia, and exhibited a hyper-inflammatory phenotype [elevated CRP, serum ferritin (SF), LDH, neutrophil-to-lymphocyte ratio (NLR), KL-6], severe lymphopenia, and higher infection rates. Prior calcineurin inhibitor (CNI) use was more common in the non-SPM group (85% vs. 62%, P = 0.001). Within the SPM group, non-survivors had shorter disease duration and higher inflammatory markers. Multivariable analysis identified longer pre-SPM disease duration (OR 0.479, 95% CI 0.266-0.863) and prior cyclophosphamide (CTX) therapy (OR 0.034, 95% CI 0.003-0.405) as factors independently associated with improved survival (both P<0.05). Conclusion: Older MDA5+DM patients with a hyper-inflammatory phenotype and fewer arthralgias are at increased risk for SPM, whereas prior CNI use may be protective. In SPM patients, elevated inflammatory markers predict poor survival, while longer pre-SPM disease duration and prior CTX therapy are associated with improved survival, suggesting early aggressive immunosuppression may improve outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.